T1	PrimaryOutcome 39 55	time to recovery
T2	OutcomeDefinition 68 971	the first day, during the 28 days after enrollment, on which a patient met the criteria for category 1, 2, or 3 on the eight-category ordinal scale. The categories are as follows: 1, not hospitalized and no limitations of activities; 2, not hospitalized, with limitation of activities, home oxygen requirement, or both; 3, hospitalized, not requiring supplemental oxygen and no longer requiring ongoing medical care (used if hospitalization was extended for infection-control or other nonmedical reasons); 4, hospitalized, not requiring supplemental oxygen but requiring ongoing medical care (related to Covid-19 or to other medical conditions); 5, hospitalized, requiring any supplemental oxygen; 6, hospitalized, requiring noninvasive ventilation or use of high-flow oxygen devices; 7, hospitalized, receiving invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); and 8, death
R1	DefinedAs Arg1:T1 Arg2:T2	
T3	SecondaryOutcome 1004 1019	clinical status
T4	TimeFrame 1020 1029	at day 15
R2	MeasuredAt Arg1:T3 Arg2:T4	
T5	OutcomeDefinition 1034 1064	assessed on the ordinal scale.
R3	DefinedAs Arg1:T3 Arg2:T5	
T6	SecondaryOutcome 1103 1192	time to improvement of one category and of two categories from the baseline ordinal score
T7	SecondaryOutcome 1194 1242	clinical status as assessed on the ordinal scale
T8	TimeFrame 1243 1278	at days 3, 5, 8, 11, 15, 22, and 29
R4	MeasuredAt Arg1:T7 Arg2:T8	
T9	SecondaryOutcome 1280 1322	mean change in status on the ordinal scale
T10	TimeFrame 1323 1369	from day 1 to days 3, 5, 8, 11, 15, 22, and 29
R5	MeasuredAt Arg1:T9 Arg2:T10	
T11	SecondaryOutcome 1371 1485	time to discharge or National Early Warning Score of 2 or less (maintained for 24 hours), whichever occurred first
T12	SecondaryOutcome 1487 1529	change in the National Early Warning Score
T13	TimeFrame 1530 1576	from day 1 to days 3, 5, 8, 11, 15, 22, and 29
R6	MeasuredAt Arg1:T12 Arg2:T13	
T14	SecondaryOutcome 1578 1758	number of days with supplemental oxygen, with noninvasive ventilation or high-flow oxygen, and with invasive ventilation or ECMO up to day 29 (if these were being used at baseline)
T15	SecondaryOutcome 1764 1889	incidence and duration of new oxygen use, of noninvasive ventilation or high-flow oxygen, and of invasive ventilation or ECMO
T16	SecondaryOutcome 1891 1924	number of days of hospitalization
T17	TimeFrame 1925 1937	up to day 29
R7	MeasuredAt Arg1:T16 Arg2:T17	
T18	SecondaryOutcome 1943 1952	mortality
T19	TimeFrame 1953 1987	at 14 and 28 days after enrollment
T20	OtherOutcome 2032 2118	grade 3 and 4 adverse events and serious adverse events that occurred during the trial
T21	OtherOutcome 2120 2172	discontinuation or temporary suspension of infusions
T22	OtherOutcome 2178 2225	changes in assessed laboratory values over time
